|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4A
|
|
pubmed:dateCreated |
1999-9-28
|
|
pubmed:abstractText |
This study was designed to determine the clinical utility of NMP22 as a urinary marker for the early detection of transitional cell carcinoma (TCC) of the bladder in patients with hematuria or other indications for risk of malignancy. Its utility will be measured by sensitivity and specificity estimates as compared to cystoscopy. Since urine cytology is normally collected in this population of patients, it will also be analyzed and compared to cystoscopy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2621-3
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10470205-Cost-Benefit Analysis,
pubmed-meshheading:10470205-Cystoscopy,
pubmed-meshheading:10470205-Female,
pubmed-meshheading:10470205-Hematuria,
pubmed-meshheading:10470205-Humans,
pubmed-meshheading:10470205-Male,
pubmed-meshheading:10470205-Middle Aged,
pubmed-meshheading:10470205-Neoplasm Staging,
pubmed-meshheading:10470205-Nuclear Proteins,
pubmed-meshheading:10470205-Predictive Value of Tests,
pubmed-meshheading:10470205-Reproducibility of Results,
pubmed-meshheading:10470205-Sensitivity and Specificity,
pubmed-meshheading:10470205-Tumor Markers, Biological,
pubmed-meshheading:10470205-United States,
pubmed-meshheading:10470205-Urinary Bladder Neoplasms
|
|
pubmed:articleTitle |
NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
|
|
pubmed:affiliation |
Cleveland Clinic Foundation, Department of Urology, OH 44195, USA.
|
|
pubmed:publicationType |
Journal Article
|
